Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax.

"C.J., K.O.D., C.F., M.H., L.Q., and F.M. are or were employees of and hold shares in GSK."

"This work was largely funded by the DTRA under Agreement No. HDTRA1-07-9-0002. We would especially like to thank the DTRA project manager Amanda Horstman Smith for her technical expertise and insights into biothreat Animal Rule studies. We also acknowledge the laboratory staff at USAMRIID who performed the in vitro work presented in this manuscript, including Lynda Miller and Stephanie Halasohoris. In addition, we acknowledge the staff at Battelle, including Denise Pfefferle, Megan Posey, Joe Wickham, Michelle Sunderman, Jill Staugler, Andy Puttmann, Brent McCracken, Meredith Kirkbride, Mike Mladineo, and Dennis Pak. Further, we thank the entire GSK team, including Jennifer Hoover, Scott Sucoloski, Sean Maguire, Lorrie Day, Steve Lerman, and Kitaw Negash. In particular, we acknowledge Mick Gwynn, the discoverer of the novel bacterial topoisomerase inhibitors (NBTI) class of antibacterials, who passed away on December 16, 2013. This work was supported by GSK and largely funded by the DTRA under Agreement No. HDTRA1-07-9-0002. Editorial support for the manuscript was funded by GSK."